Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 15/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21264510 | 0.91 | MET (0.64) | METNQO2 | |
| SCHEMBL21264867 | 0.86 | MET (0.55) | METNQO2KDM1AMAOBAKT1 | |
| SCHEMBL21264617 | 0.86 | MET (0.51) | METNQO2 | |
| SCHEMBL21264620 | 0.83 | L3MBTL1 (0.45) | METNQO2 | |
| SCHEMBL22309763 | 0.81 | MET (0.53) | METNQO2KDM1AMAOBAKT1 | |
| SCHEMBL21322013 | 0.81 | MET (0.49) | METNQO2KDM1AMAOB | |
| SCHEMBL21264869 | 0.81 | MET (0.60) | METNQO2KDM1AMAOB | |
| SCHEMBL21264847 | 0.81 | MET (0.50) | METNQO2KDM1A | |
| Hydrochloric Acid SCHEMBL28511706 | 0.79 | MET (0.73) | METNQO2 | |
| SCHEMBL25071677 | 0.79 | MET (0.50) | METNQO2KDM1AMAOBAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501443-B2 | Pyridone compound as c-met inhibitor | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2019-12-10 | — | — | US | disclosed |
| US-20190248763-A1 | PYRIDONE COMPOUND AS C-MET INHIBITOR | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248763-A1 | PYRIDONE COMPOUND AS C-MET INHIBITOR | MET, PDXK, RET | MET 1/4885NQO2 2416/4885KDM1A 1641/4885 |
| US-10501443-B2 | Pyridone compound as c-met inhibitor | MET, PDXK, RET | MET 1/4885NQO2 2416/4885KDM1A 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.